These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Trauner M; Fickert P; Wagner M Semin Liver Dis; 2007 Feb; 27(1):77-98. PubMed ID: 17295178 [TBL] [Abstract][Full Text] [Related]
25. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Kamath BM; Stein P; Houwen RHJ; Verkade HJ Liver Int; 2020 Aug; 40(8):1812-1822. PubMed ID: 32492754 [TBL] [Abstract][Full Text] [Related]
26. Pediatric Cholestatic Diseases: Common and Unique Pathogenic Mechanisms. Sutton H; Karpen SJ; Kamath BM Annu Rev Pathol; 2024 Jan; 19():319-344. PubMed ID: 38265882 [TBL] [Abstract][Full Text] [Related]
27. Clinical and pathological characteristics of Alagille syndrome in Chinese children. Wang JS; Wang XH; Zhu QR; Wang ZL; Hu XQ; Zheng S World J Pediatr; 2008 Nov; 4(4):283-8. PubMed ID: 19104892 [TBL] [Abstract][Full Text] [Related]
28. Treatment of Cholestasis in Infants and Young Children. Heinz N; Vittorio J Curr Gastroenterol Rep; 2023 Nov; 25(11):344-354. PubMed ID: 37651067 [TBL] [Abstract][Full Text] [Related]
29. Rodent models of cholestatic liver disease: A practical guide for translational research. Gijbels E; Pieters A; De Muynck K; Vinken M; Devisscher L Liver Int; 2021 Apr; 41(4):656-682. PubMed ID: 33486884 [TBL] [Abstract][Full Text] [Related]
30. Surgical outcomes in Alagille syndrome and PFIC: A single institution's 20-year experience. Flores CD; Yu YR; Miloh TA; Goss J; Brandt ML J Pediatr Surg; 2018 May; 53(5):976-979. PubMed ID: 29729773 [TBL] [Abstract][Full Text] [Related]
32. Endoscopic approach to the patient with congenital anomalies of the biliary tract. Liu QY; Nguyen V Gastrointest Endosc Clin N Am; 2013 Apr; 23(2):505-18. PubMed ID: 23540973 [TBL] [Abstract][Full Text] [Related]
33. Medical management of chronic cholestatic liver diseases. Gossard AA; Lindor KD Can J Gastroenterol; 2000 Nov; 14 Suppl D():93D-98D. PubMed ID: 11110620 [TBL] [Abstract][Full Text] [Related]
36. Diagnostic utility of hepatobiliary scintigraphy with 99mTc-DISIDA in neonatal cholestasis. Spivak W; Sarkar S; Winter D; Glassman M; Donlon E; Tucker KJ J Pediatr; 1987 Jun; 110(6):855-61. PubMed ID: 3585600 [TBL] [Abstract][Full Text] [Related]
37. Hepatobiliary complications of oral contraceptives. Lindberg MC J Gen Intern Med; 1992; 7(2):199-209. PubMed ID: 1336797 [TBL] [Abstract][Full Text] [Related]
38. Effect of drug transporter pharmacogenetics on cholestasis. Dietrich CG; Geier A Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1533-51. PubMed ID: 25260651 [TBL] [Abstract][Full Text] [Related]
39. Development of the Patient- and Observer-Reported PRUCISION Instruments to Assess Pruritus and Sleep Disturbance in Pediatric Patients with Cholestatic Liver Diseases. Gwaltney C; Bean S; Venerus M; Karlsson L; Warholic N; Kjems L; Horn P Adv Ther; 2022 Nov; 39(11):5126-5143. PubMed ID: 36066744 [TBL] [Abstract][Full Text] [Related]
40. ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression. Degiorgio D; Crosignani A; Colombo C; Bordo D; Zuin M; Vassallo E; Syrén ML; Coviello DA; Battezzati PM J Gastroenterol; 2016 Mar; 51(3):271-80. PubMed ID: 26324191 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]